Aravax is a clinical stage biotechnology company developing a novel peptide-based immunotherapy, PVX108, for the treatment of peanut allergy. Aravax is striving to improve the lives of patients living with peanut allergies by developing a therapy that precisely targets the underlying cause of disease, bringing benefits in safety and convenience.

Biotechnology

Life Sciences

Therapeutics

Aravax

Aravax's headquarters in Melbourne, Australia

The Oxford office focuses on advancing pharmaceutical research and development initiatives in the United Kingdom.

People (1)

Jobs (0)

Other offices